Unexpected Role of MPO-Oxidized LDLs in Atherosclerosis: In between Inflammation and Its Resolution

Area of Science:

• Cardiovascular Research
• Inflammation Biology
• Oxidative Stress Mechanisms

Background:

• Atherosclerosis is a chronic inflammatory disease where the balance between pro-inflammatory and pro-resolving factors is critical.
• Myeloperoxidase (MPO) is linked to oxidative stress and atherosclerosis, producing MPO-oxidized low-density lipoproteins (Mox-LDLs).
• Mox-LDLs influence foam cell formation, macrophage polarization, and reactive oxygen species (ROS) production.

Purpose of the Study:

• To explore the complex interplay between MPO, Mox-LDLs, and specialized pro-resolving mediators (SPMs) in atherosclerosis.
• To elucidate the dual role of Mox-LDLs in modulating inflammatory and pro-resolving pathways.
• To highlight a novel perspective on Mox-LDL involvement in atherosclerotic plaque evolution.

Main Methods:

• Review of existing literature on MPO, Mox-LDLs, SPMs, and their interactions in atherosclerosis.
• Analysis of in vitro studies examining Mox-LDL effects on endothelial cells and macrophages.
• Discussion of the mechanisms by which Mox-LDLs influence inflammatory responses and resolution mediators.

Main Results:

• Mox-LDLs exhibit pro-inflammatory properties, increasing ROS production and driving macrophage polarization.
• Endothelial cells exposed to Mox-LDLs produce resolvin D1 (RvD1), a key SPM.
• In vitro, Mox-LDLs demonstrate a mixed effect, promoting RvD1 release and inducing anti-inflammatory macrophage phenotypes.

Conclusions:

• Mox-LDLs have a dual role in atherosclerosis, acting as pro-inflammatory agents while also triggering the production of pro-resolving mediators.
• The interaction between Mox-LDLs and SPMs like RvD1 presents a new understanding of inflammation resolution in atherosclerosis.
• Further research into this complex interplay could reveal novel therapeutic targets for managing atherosclerosis.